Payment overview · 2025
General Payments
$1,438.70
78 reported records · 21 companies
Healthcare provider profile · identity verified
Brad C Erikson, DO
Allopathic & Osteopathic Physicians|Family Medicine · IDAHO FALLS, ID · NPI 1164477931
Verified facts
What the public records show
CMS Open Payments records show Brad C Erikson, DO received $1,438.70 in general payments during 2025 across 78 reported records.
ABBVIE INC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.68 | 17.9% | 17 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $243.50 | 16.9% | 11 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.37 | 8.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.01 | 8.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.54 | 6.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.82 | 6.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.62 | 5.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.63 | 4.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $54.50 | 3.8% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $49.82 | 3.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.41 | 3.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.84 | 2.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.61 | 2.2% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $29.26 | 2.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.61 | 1.5% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.28 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $19.14 | 1.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.66 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.17 | 1.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.97 | 1.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.26 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,438.70 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $243.50 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $165.05 | 9 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.37 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $121.01 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $95.54 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.63 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.62 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $66.78 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $66.10 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.97 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.63 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $54.50 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.65 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $29.26 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.57 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 80 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 542 | 148 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 342 | 95 |
| Gabapentin | Gabapentin | 335 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 292 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 78 |
| Metformin Hcl Er | Metformin Hcl | 249 | 65 |
| Lisinopril | Lisinopril | 237 | 62 |
| Tramadol Hcl | Tramadol Hcl | 227 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 63 |
| Celecoxib | Celecoxib | 214 | 58 |
| Losartan Potassium | Losartan Potassium | 211 | 53 |
| Trazodone Hcl | Trazodone Hcl | 196 | 49 |
| Bupropion Xl | Bupropion Hcl | 191 | 44 |
| Meloxicam | Meloxicam | 186 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 46 |
| Famotidine | Famotidine | 171 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 154 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 148 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 145 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 143 | 29 |
| Potassium Chloride | Potassium Chloride | 138 | 39 |
| Furosemide | Furosemide | 131 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 33 |
| Alprazolam | Alprazolam | 126 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 24 |
| Ozempic | Semaglutide | 114 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 113 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 110 | 35 |
| Simvastatin | Simvastatin | 102 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 32 |
| Eliquis | Apixaban | 95 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 28 |
| Sertraline Hcl | Sertraline Hcl | 93 | 22 |
| Pregabalin | Pregabalin | 89 | 17 |
| Allopurinol | Allopurinol | 87 | 28 |
| Aripiprazole | Aripiprazole | 81 | 18 |
| Estradiol | Estradiol | 81 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 21 |
| Carvedilol | Carvedilol | 80 | 19 |
| Clonazepam | Clonazepam | 80 | 14 |
| Mounjaro | Tirzepatide | 80 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 14 |
| Montelukast Sodium | Montelukast Sodium | 76 | 27 |
| Metformin Hcl | Metformin Hcl | 70 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 65 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 11 |
| Valsartan | Valsartan | 60 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 37 |
| Finasteride | Finasteride | 58 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 58 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 21 |
| Buspirone Hcl | Buspirone Hcl | 55 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 18 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Ibuprofen | Ibuprofen | 49 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 18 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 48 | 16 |
| Cephalexin | Cephalexin | 46 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Temazepam | Temazepam | 39 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 35 | 12 |
| Sulindac | Sulindac | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Buprenorphine | Buprenorphine | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 17 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Sotalol | Sotalol Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Modafinil | Modafinil | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Brilinta | Ticagrelor | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 11 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,438.70 · 78 records | ABBVIE INC. | Auvelity, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FANAPT, GEMTESA, INCEPTIV, INJECTAFER, INSPIRE, KRYSTEXXA, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, SPRAVATO, Sunosi, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error